# Sequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency Diseases

> **NCT01852370** · PHASE1,PHASE2 · ENROLLING_BY_INVITATION · sponsor: **Paul Szabolcs** · enrollment: 16 (estimated)

## Conditions studied

- Severe Combined Immunodeficiency (SCID)
- Immunodeficiency With Predominant T-cell Defect, Unspecified
- Severe Chronic Neutropenia
- Chronic Granulomatous Disease (CGD)
- Hyper IgE Syndromes
- Hyper IgM Deficiencies
- Wiskott-Aldrich Syndrome
- Mendelian Susceptibility to Mycobacterial Disease
- Common Variable Immune Deficiency (CVID)

## Interventions

- **BIOLOGICAL:** CD3/CD19 negative allogeneic hematopoietic stem cells

## Key facts

- **NCT ID:** NCT01852370
- **Lead sponsor:** Paul Szabolcs
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2013-06-20
- **Primary completion:** 2026-11
- **Final completion:** 2027-11
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2025-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01852370

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01852370, "Sequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency Diseases". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01852370. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*